WIXOM, MI — (Marketwired) — 05/20/13 — Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today PRIME clinical study results for Soluble Ferric Pyrophosphate (SFP) at the 50^th ERA-EDTA congress in Istanbul, Turkey. SFP is the Company’s investigational iron-delivery drug for the treatment of iron deficiency in hemodialysis patients, nearing completion of its Phase 3 clinical studies. Dr. Ajay Gupta, MD, Chief Scientific Officer of Rockwell presented the PRIME study results at the Late Breaking Clinical Trials session. This is fully-analyzed data, including atypical data subsequently found in a few study subjects, superseding initial top-line data announced Feb 4, 2013.

“SFP is a very promising parenteral iron supplement for the treatment of anemia in CKD-HD patients and could address the unmet need of correcting their functional iron deficiency,” stated Professor Francesco Locatelli, MD, Scientific Director of the Department of Nephrology, Dialysis and Renal Transplantation at Alessandro Manzoni Hospital Lecco, Italy. “The results of this study are important as it is the first demonstration that administration of soluble iron salts can be achieved safely without the risk of high serum iron concentrations, which can potentially lead to oxidative stress. This study further demonstrates the potential for reducing IV iron and/or ESA doses while maintaining hemoglobin levels in CKD-HD patients.”

“We are very pleased to present the exciting results of this well-run study,” stated Dr. Raymond Pratt, Chief Medical Officer of Rockwell Medical. “The SFP dose of 11 µg iron/dL dialysate delivered sufficient iron without increasing iron stores while greatly reducing ESA and IV iron requirements. The safety profile of SFP was excellent. The fact that the incidence of intra-dialytic hypotension was numerically less in SFP compared to placebo group supports the safety of SFP-iron delivery via dialysate. The 35% higher ESA dose required in the placebo arm to maintain hemoglobin compared to the SFP arm, supports our belief that SFP will demonstrate efficacy in the Phase 3 CRUISE clinical studies, where ESA titration and IV iron is not permitted.”

The PRIME study was a nine-month, prospective, randomized, placebo-controlled, double-blinded, multi-center study in United States that randomized 108 patients equally to dialysate containing SFP-iron versus conventional dialysate. A total of 103 patients received blinded study drug (52 SFP, 51 Placebo; modified ITT population). In all study patients, ESA doses were titrated to maintain hemoglobin in a target range of 9.5 to 11.5 g/dL according to an algorithm managed by an independent centralized anemia management group. At the end of treatment, the hemoglobin value in the SFP group was 10.5 g/dL and 10.4 g/dL in the placebo group. Intravenous (IV) iron was administered according to a protocol to treat iron deficiency.

The primary objective of the study was to determine whether regular administration of SFP via dialysate reduced the requirement for ESA dose by maintaining iron balance and optimizing iron delivery. The primary endpoint was the percent change in ESA dose from baseline to end of treatment (final two weeks of treatment period). Baseline ESA dose was similar between SFP (9483 U/wk) and placebo (9205 U/wk). In the modified ITT population, at the end of the study, ESA dose in the SFP arm was 9871 U/wk and placebo was 12628 U/wk. After adjusting for differences in baseline hemoglobin, the SFP arm required 35% less prescribed ESA compared to placebo. The difference between the two groups was statistically significant (p=0.045). The ESA sparing effect from SFP was observed without any increase in serum ferritin or pre-dialysis transferrin saturation. The PRIME study demonstrated that regular administration of SFP-iron via dialysate reduced the usage of erythropoietin stimulating agents (ESAs) during hemodialysis by 35% while maintaining iron balance and maximizing iron delivery.

The adverse event profile of the SFP group was similar to placebo with respect to event, frequency and severity. The numbers and types of serious adverse events were also similar in both groups. Importantly the incidence, frequency and severity of intradialytic hypotension in the SFP group were similar to placebo. There were no hypersensitivity or anaphylactoid reactions reported in the SFP group over the 9 months of the study.

About SFP
SFP is a unique iron compound that is delivered to the hemodialysis patient via dialysate, replacing the 5-7 mg of iron lost during a dialysis treatment. SFP is introduced into the sodium bicarbonate concentrate that subsequently is mixed into dialysate. Once in the dialysate, SFP crosses the dialyzer membrane and enters the bloodstream where it immediately binds to apo-transferrin and is taken to the bone marrow, mimicking the way dietary iron is processed in the human body. In completed clinical trials to date, SFP has demonstrated that it can safely deliver iron and maintain hemoglobin levels, while decreasing ESA use without an increase in iron stores.

About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell’s lead drug candidate in late-stage clinical development is for the treatment of iron deficiency in dialysis patients and is called Soluble Ferric Pyrophosphate (SFP). SFP delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner via dialysate during their regular dialysis treatment. In completed clinical trials to date, SFP has demonstrated that it can safely deliver sufficient iron to the bone marrow. SFP is nearing completion of its Phase 3 clinical studies (CRUISE-1 and CRUISE-2) and is expected to address an estimated $600M U.S. market.

Rockwell is preparing to launch its FDA approved generic drug called Calcitriol to treat secondary hyperparathyroidism in dialysis patients. Calcitriol active vitamin D injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to launch Calcitriol as soon as it receives FDA manufacturing approval, addressing an estimated $350M U.S. market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three manufacturing and distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP upon FDA market approval.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP’s unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to launch Calcitriol and SFP following FDA approval. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Michael Rice
Investor Relations
646-597-6979

David Connolly
Media Contact
617-374-8800

Source: Rockwell Medical Technologies, Inc.

“The only way to discover the limits of the possible is to go beyond them into the impossible.”” -Arthur C. Clarke

As you may remember from previous posts, Richmond Brothers’ Above & Beyond recognition program is a way for employees to provide a feedback loop to each other, recognizing the positive impacts they have made. The program parallels with Richmond Brothers’ core values and mission statement.

We are proud to announce there was a tie with our first quarter Above & Beyond winners, Sue VanEyck and Cindy Ott. These two wonderful ladies provided the most acts that went the extra mile for both clients and co-workers alike. In addition to that tie, they also both recognized and awarded the most instances that their co-workers did more than what was required for their normal job duties.

Sue was recognized for her positive attitude and treating her co-workers to a sweet snack, among other things. Cindy was instrumental in providing extra help with office projects and keeping office supplies stocked for co-workers, just to name a few.

Congratulations, you two! You are well-deserving of this award!

Companies Solidify and Expand Their Business Relationship

WIXOM, Mich., May 8, 2013 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today they have signed a multi-year, national product supply agreement with DaVita, the dialysis division of DaVita HealthCare Partners, Inc. The supply agreement includes a significant increase in the number of DaVita dialysis clinics that will purchase product from Rockwell, and covers a five-year period.

“We are pleased to enter into this agreement and expand our business with DaVita,” stated Rob Chioini, Chairman and CEO of Rockwell. ”This multi-year supply agreement will significantly expand our business. It includes the conversion to our CitraPure^® concentrate line and provides an avenue for future sales of new Rockwell products.”

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500^® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. As of December 31, 2012, DaVita operated or provided administrative services at 2,000 outpatient dialysis centers located in the United States serving approximately 153,000 patients. The company also operated 36 outpatient dialysis centers located in five countries outside the United States.

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. 

Rockwell’s lead drug candidate in late-stage clinical development is for the treatment of iron deficiency in dialysis patients and is called Soluble Ferric Pyrophosphate (SFP). SFP delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner via dialysate during their regular dialysis treatment. In completed clinical trials to date, SFP has demonstrated that it can safely deliver sufficient iron to the bone marrow. SFP is nearing completion of its Phase 3 clinical studies (CRUISE-1 and CRUISE-2) and is expected to address an estimated $600M U.S. market. 

Rockwell is preparing to launch its FDA approved generic drug called Calcitriol to treat secondary hyperparathyroidism in dialysis patients. Calcitriol active vitamin D injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to launch Calcitriol as soon as it receives FDA manufacturing approval, addressing an estimated $350M U.S. market.  

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life, by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three manufacturing and distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP upon FDA market approval. 

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP’s unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

The Rockwell Medical Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6773

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Michael Rice, Investor Relations at 646-597-6979

         David Connolly, Media Contact at 617-374-8800

Source: Rockwell Medical, Inc.

- Compelling PRIME Data, Calcitriol Manufacturing Submission Highlight Q1-

- Company to expand business with DaVita via multi-year supply deal –

WIXOM, Mich., May 8, 2013 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, reported financial results for the first quarter of 2013.

Q1 2013 Highlights

• Sales were $12.3 million, an increase of 2.6% over Q1 2012.
• Domestic sales increased 5.5% over Q1 2012.
• Gross profit decreased $300,000, primarily due to higher material and operational costs.
• Cash and investments aggregated $5.8 million as of March 31, 2013.

Drug Development Highlights

• Calcitriol (active vitamin D) injection data was submitted to FDA for manufacturing approval.
• PRIME clinical data showing 35% ESA reduction to be presented at upcoming ERA-EDTA, Istanbul, Turkey.
• CRUISE-1 top-line data projected Q3 2013; CRUISE-2 top-line data projected Q4 2013.

For the quarter, Rockwell reported a loss of ($15.4) million or ($0.72) per share compared to ($10.6) million or ($0.54) per share in the first quarter of 2012. R&D costs were $12.75 million compared to $9.4 million in the first quarter of 2012. Non-cash charges for equity compensation and warrant revaluation expense were $2.3 million.

“We achieved two very important clinical goals in Q1,” stated Rob Chioini, Founder, Chairman and CEO of Rockwell Medical. “First, our SFP clinical data from the PRIME study was excellent, showing an impressive reduction in the need for ESA and supporting our belief that SFP will demonstrate efficacy in the Phase 3 CRUISE clinical studies. Second, we submitted our Calcitriol manufacturing data to the FDA, which was the last major step we needed to complete to be able to launch the drug commercially. Once we get approval confirmation from the FDA, we plan to offer Calcitriol to dialysis providers across the U.S. and we are optimistic that we will have success gaining sales.”

Mr. Chioini further stated, “Our domestic sales were in line with our expectations. Going forward we expect to see increased sales growth, notably from our CitraPure^® product line, new product offerings and from the increased commitment in our new supply contract with DaVita.”

Conference Call Information

Rockwell Medical will be hosting a conference call to review its first quarter 2013 results on Wednesday, May 8, 2013 at 4:30 pm ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438, passcode #64250555 or to listen to the call via webcast at the Rockwell Medical IR web page: http://ir.rockwellmed.com/

About SFP

SFP is a unique iron compound that is delivered to the hemodialysis patient via dialysate, replacing the 5-7mg of iron lost during a dialysis treatment. SFP is introduced into the sodium bicarbonate concentrate that subsequently is mixed into dialysate. Once in the dialysate, SFP crosses the dialyzer membrane and enters the bloodstream where it immediately binds to apo-transferrin and is taken to the bone marrow, mimicking the way dietary iron is processed in the human body. In completed clinical trials to date, SFP has demonstrated that it can safely deliver iron and maintain hemoglobin levels, while decreasing ESA use without an increase in iron stores.

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. 

Rockwell’s lead drug candidate in late-stage clinical development is for the treatment of iron deficiency in dialysis patients and is called Soluble Ferric Pyrophosphate (SFP).  SFP delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner via dialysate during their regular dialysis treatment. In completed clinical trials to date, SFP has demonstrated that it can safely deliver sufficient iron to the bone marrow. SFP is nearing completion of its Phase 3 clinical studies (CRUISE-1 and CRUISE-2) and is expected to address an estimated $600M U.S. market. 

Rockwell is preparing to launch its FDA approved generic drug called Calcitriol to treat secondary hyperparathyroidism in dialysis patients. Calcitriol active vitamin D injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to launch Calcitriol as soon as it receives FDA manufacturing approval, addressing an estimated $350M U.S. market.   

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream.  Rockwell has three manufacturing and distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP upon FDA market approval. 

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience.  Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP’s unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

The Rockwell Medical Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6773

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to launch Calcitriol and SFP following FDA approval. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Michael Rice, Investor Relations; (646) 597-6979

         David Connolly, Media Contact; (617) 374-8800

Source: Rockwell Medical, Inc.

Keating Capital received total proceeds of $8.7 million from the sale of its LifeLock position (after selling expenses), compared to a fair value of $9.1 million as of March 31, 2013, and a cost of $5.0 million. The shares of LifeLock common stock sold by Keating Capital were received upon the conversion of LifeLock’s Series E Convertible Preferred Stock, which Keating Capital initially acquired on March 14, 2012. The Series E round raised over $100 million from Keating Capital and other co-investors, including Bessemer Venture Partners, Goldman, Sachs & Co., Kleiner Perkins Caufield & Byers, and Symantec Corporation.

The Company’s sale of its entire LifeLock position represented a return multiple of 1.74x its investment cost over a holding period of 1.1 years. This represents an internal rate of return, or IRR, on this investment of approximately 66% per year.

The Company’s Board of Directors currently intends to declare a distribution of at least 90% of the LifeLock realized gains, subject to any gains or losses realized on other portfolio company investments. At the Company’s next quarterly Board meeting scheduled for July 25, 2013, the Company expects that the Board will take further action concerning the distribution of the LifeLock realized gains.

“The LifeLock investment was an unqualified success for us and a case study of how we believe our private-to-public valuation arbitrage model is expected to work,” stated Timothy J. Keating, CEO of Keating Capital. “We invested in a growing, category leading, high profile company alongside a number of top tier venture capital firms, many of whom we have co-invested with in the past. The investment size of $5 million was our largest at the time and one of four of equal size that we have made. The 1.74x return multiple we achieved over of a holding period of 1.1 years was in line with our targeted 2x return multiple over our anticipated four-year holding period,” added Mr. Keating.

LifeLock was the Company’s third out of 20 portfolio company investments to complete its IPO, and the sale of the LifeLock position is the second complete exit for Keating Capital.

About Keating Capital, Inc.

Keating Capital is a business development company that specializes in making pre-IPO investments in innovative, emerging growth companies that are committed to and capable of becoming public. We provide investors with the ability to participate in a unique fund that allows our stockholders to share in the potential value accretion that we believe typically occurs once a company transforms from private to public status. Keating Capital’s shares are listed on Nasdaq under the ticker symbol “KIPO.”

To be added to Keating Capital’s email distribution list to receive quarterly newsletters and other announcements, go to www.KeatingCapital.com/contact.

Forward-Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect Keating Capital’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release, including the factors set forth in “Risk Factors” set forth in Keating Capital’s Form 10-K and Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and subsequent filings with the SEC. Please refer to Keating Capital’s SEC filings for a more detailed discussion of the risks and uncertainties associated with its business, including but not limited to the risks and uncertainties associated with investing in micro- and small-cap companies. Except as required by the federal securities laws, Keating Capital undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to Keating Capital’s website has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

• Monthly Distribution Letter (May 1, 2013)
• Q1 2013 Earnings Webcast – May 30, 2013 – 2:00 PM CT

Reminder:  The annual meeting will be held on Wednesday, June 12, 2013, at the Inland Corporate Office, 2901 Butterfield Road, Oak Brook, Illinois, commencing at 10:00 AM CT.

For further information, contact Inland Investor Services at 800.826.8228 or visit the website at www.inlanddiversified.com.

This is neither an offer to sell nor a solicitation of an offer to buy any security, which can only be made by a prospectus which has been filed with the appropriate state and federal regulatory agencies and sold only by broker dealers authorized to do so.

The Inland name and logo are registered trademarks being used under license. This material has been distributed by Inland Securities Corporation, dealer manager for Inland Diversified Real Estate Trust, Inc. Inland Securities Corporation, member FINRA/SIPC.

This call is also being webcast and can be accessed at the Rockwell Medical IR web page. You can join this call on:

Wednesday, May 8, 2013
Starting at 4:30pm EDT
Dial in number: 877-383-7438
International dial in: 678-894-3975
Passcode: 64250555
Webcast: http://ir.rockwellmed.com

About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell’s lead drug candidate in late-stage clinical development is for the treatment of iron deficiency in dialysis patients and is called Soluble Ferric Pyrophosphate (SFP). SFP delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner via dialysate during their regular dialysis treatment. In completed clinical trials to date, SFP has demonstrated that it can safely deliver sufficient iron to the bone marrow. SFP is nearing completion of its Phase 3 clinical studies (CRUISE-1 and CRUISE-2) and is expected to address an estimated $600M U.S. market.

Rockwell is preparing to launch its FDA approved generic drug called Calcitriol to treat secondary hyperparathyroidism in dialysis patients. Calcitriol active vitamin D injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to launch Calcitriol as soon as it receives FDA manufacturing approval, addressing an estimated $350M U.S. market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three manufacturing and distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP upon FDA market approval.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP’s unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to launch Calcitriol and SFP following FDA approval. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Michael Rice
Investor Relations
(646) 597-6979

David Connolly
Media Contact
(617) 374-8800

Source: Rockwell Medical Technologies, Inc.

Management Commentary

“Although we made no additional investments in the first quarter, we have sold about 74% of our LifeLock shares since first quarter-end through April 25, 2013 resulting in approximately $2.7 million of net realized gains. Based on 9,132,222 shares of our common stock outstanding as of March 31, 2013, these LifeLock realized gains represent approximately $0.30 per share. Our Board currently intends to declare a distribution of at least 90% of our LifeLock realized gains, subject to any gains or losses realized on other portfolio company investments. At our next quarterly Board meeting scheduled for July 25, 2013, we expect that our Board will take further action concerning the distribution of our LifeLock realized gains following the disposition of our entire LifeLock position. These realized gains, as well as any further dispositions we may make during the second quarter, will be reflected in our second quarter financial results,” stated Timothy J. Keating, CEO of Keating Capital, Inc.

Click here to read the complete press release.

About Keating Capital, Inc.

Keating Capital is a business development company that specializes in making pre-IPO investments in innovative, emerging growth companies that are committed to and capable of becoming public. We provide investors with the ability to participate in a unique fund that allows our stockholders to share in the potential value accretion that we believe typically occurs once a company transforms from private to public status. Keating Capital’s shares are listed on Nasdaq under the ticker symbol “KIPO.”

Forward-Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect Keating Capital’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release, including the factors set forth in “Risk Factors” set forth in Keating Capital’s Form 10-K and Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and subsequent filings with the SEC. Please refer to Keating Capital’s SEC filings for a more detailed discussion of the risks and uncertainties associated with its business, including but not limited to the risks and uncertainties associated with investing in micro- and small-cap companies. Except as required by the federal securities laws, Keating Capital undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to Keating Capital’s website has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

Investor Relations Contact:
Margie L. Blackwell
Investor Relations Director
Keating Capital, Inc.
mb@keatinginvestments.com
(720) 889-0133

Keating Capital, Inc. (“Keating Capital”) is a Maryland corporation that has elected to be regulated as a business development company under the Investment Company Act of 1940. Keating Investments, LLC (“Keating Investments”) is an SEC registered investment adviser and acts as an investment adviser and receives base management and/or incentive fees from Keating Capital. Keating Investments and its affiliates, control persons, and related individuals or entities may invest in the businesses or securities of the companies for whom Keating Capital provides managerial assistance in connection with its investments. Investment advisory services are provided by Keating Investments. Keating Investments and Keating Capital operate under the generic name of Keating.

Mr. Tom Claridge, Senior Mining and Plant Engineer, stated, “Steve Eady, our Chief Geologist, and I continue to systematically assess the project and its potential. Once the metallurgical work is completed, we will test the processing options outlined. The results to date continue to be encouraging.”

The Ponderosa Project consists of 6,721 acres of both patented and unpatented mining claims in central Idaho, USA. The optioned claims include previously mined veins with historic sampling of the exposed outcrops averaging 14 grams/tonne gold. Tara’s initial focus is to assess the previously un-mined veins for their near-term production potential.

About Tara Minerals Corp. (http://www.TaraMinerals.com)

Tara currently has 100% ownership in over 39 square miles (25,770 acres) in the Don Roman district located in the northern part of the La Reforma Mining District of northeastern Sinaloa State, Mexico. Tara Minerals Corp. is focused on prioritizing and the delineation of an estimated 70+ Don Roman Gold, Silver, Zinc, and Lead mineralized structures for 2013 production. Management is creating long-term shareholder value and deploying its capital to advance its projects by enhancing resources, further outlining new discoveries/targets, and acquiring additional strategic assets. The sale of the Picacho Gold/Silver project, to Yamana Gold, brought an initial payment of $7.5 million, with a second payment of $9.8 million due in May 2013. Tara’s strength in recognizing value early and strategy of reducing risk through a foundation of cash flow, positions it for low-risk value creation.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the Company’s control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. Please read the full disclaimer at www.TaraMinerals.com (http://taraminerals.com/English/General/Disclaimer/default.aspx).

Contact:

David Barefoot

(888) 901-4550

Email Contact

Source: Tara Minerals Corp.